LIMK1

Across TCGA pan-cancer cohorts, LIMK1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated LIMK1 data layer compared with 29 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher LIMK1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated LIMK1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUAD show a favorable association.

UCEC, LUAD, and PDAC are the cancer types where LIMK1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Tertile	II,III,IV	1.000	0.449	.006	36	view →
LUAD	DFS	Quartile	II,III,IV	0.647	0.337	.009	12	view →
PDAC	OS	Median	III,IV	0.610	0.882	.014	12	view →
LSCC	OS	Median	All	1.000	0.938	.013	10	view →
HNSC	DFS	Tertile	IV	0.780	0.526	.038	2	view →
GBM	DFS	Quartile	All	0.518	0.869	.026	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

LIMK1–UCEC (OS)

Open the UCEC breakdown →